


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

 · -				
In re application of:	Brown, et al.			
International App. No	D.: PCT/US2003/033317	Group Art Unit:		
International Filing I	Date: October 10. 2003	Examiner:		
For:		IDS		
Commissioner for I Washington, D.C.	Patents 20231			
	CHEMICAL COMPOUNDS Tr for Patents D.C. 20231 INFORMATION DISCLOSURE STATEMENT Ints request that the references identified on Form PTO-1449 appended hereto be considered by the difficially made of record in accordance with the provisions of 37 CFR 1.97 interest of the references are enclosed of the references were submitted in parent application Serial No. (37 CFR 1.98(d)) oppy of the International Search Report which issued on International Application No. (17 CFR 1.98(d)) oppy of the International Search Report which issued on International Application No. (17 CFR 1.98(d)) opposed to the references were submitted in parent application scited in the International Search Report which issued on International Application No. (17 CFR 1.98(d)) opposed to the remailing Search Report which issued on International Application No. (17 CFR 1.98(d)) opposed to the attached form PTO-1449 and Applicants understand that copies have been supplied the U.S. Patent Office by the International Bureau. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b). The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)). The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, hichever occurs first. Applicant hereby certifies			
Applicants req Examiner and offici	uest that the references identified ally made of record in accordance	d on Form PTO-1449 appended hereto be considered by the ce with the provisions of 37 CFR 1.97		
[] Copies of [X] A copy of PCT/US20 Report are	the International Search Report 103/033317 is submitted herewit listed on the attached form PTC Patent Office by the Internation	th. All of the publications cited in the International Search 0-1449 and Applicants understand that copies have been supplied all Bureau.		
f 2	iling date of the above application or before the mailing occurs last. 37 CFR 1.97(b).	date of a first Office action on the merits, whichever event		
OR []	The Information Disclosure Stops of a first office action after the C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).		
filing an ir ever (1) (2) whichey	g date of the above application of a ternational application or after to toccurred last, but before the man final action under § 1.113 a notice of allowance under coccurs first.	the mailing date of the first Office Action on the merits, whichever the mailing date of either: 3 or 1 § 1.311,		
Stat	ement was cited in a communication not more than three more	on the filing of this statement.		
53 A	icant elects the option to pay the losure Statement under § 1.97(c	e fee set forth in 37 CFR 1.17(p) for submission of an Information		



C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the
		issue fee. Also enclosed is a copy of the International Search Report which Issued on International
		Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [] A duplicate copy of this paper is attached.

Respectfully Submitted,

Jennifer L. Fox Agent for Appliant

Registration No. 52,218

Date: Thosas GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-6334 Facsimile: (919) 483-7988

					4		10/53	0.810
					JC13 R	ec'd PCTA	PTO 08	APR' Mon
FORM PT	O-144	9			ATTORNEY DOCKET		10/530810 PTO 08 APR 2000	
		N DISCLOSURE	STATEMEN	Г	NO.		APP. NO.	
2 (2 0 2 2)		. 2 10 0 20 0 1 -			PU4807USW		PCT/US2003/033317	
					APPLICANT			
,					Brown et al.			
					INTERNATIONAL GROUP			
					FILING DATE			
					10/10/03			
			U.S. P.	ATENT D	OCUMENTS		T	Filing Date
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	If Appropriate
	1	6,399,773	6/4/02	Liu et al.				
	2	6,197,975	3/6/01		Goulet et al.			
				ntinue on j				
	,		FOREIG	N PATEN	T DOCUMENTS			,
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes No
								,
				ļ			-	ļ
	<u> </u>	<u></u>		<u> </u>				<u> </u>
		WED DOCUME		ontinue on		4. D N.		
	01	HER DOCUME	UN 18 (Includin	ig Autnor,	Title, Journal-Da	ite, Page Nu	mber, Etc.)	
	<u> </u>							
				*	*****			
	 							
	 							
-				-				
, .	ļ							
	<u> </u>							·
-			C	ontinue on	page	TD 4 mmm :	TONIGHT TO	
EXAMINER						DATE	CONSIDERED)
					tation is in conform			

Express Mail Label: EV330919458US

applicant.